American Society of Hirudotherapy

Identifying factors affecting outcomes in scalp replantation: a systematic review of the literature

Systematic review published in J Reconstr Microsurg (2021)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Systematic reviewClinical LiteratureKotamarti VS et al. · Journal of reconstructive microsurgery, 2022

Abstract

BACKGROUND:  Replantation is the ideal treatment in traumatic scalp defects to provide immediate coverage with restoration of hair-bearing skin. However, data are limited to case reports and small case series. Comprehensive analysis of techniques and outcomes is not available. Our aim was to systematically analyze the available literature to better understand management and postoperative outcomes of patients undergoing scalp replantation. METHODS:  A systematic review of the PubMed, Cochrane, and EBSCO databases was performed in October 2019. Search terms included "replantation," "replant," "revascularized," "revascularization," "avulsion," and "scalp." Only papers reporting microvascular replantation of completely avulsed scalps, including case reports, were included. Review articles, non-English language articles, articles discussing nonreplant coverage, incomplete scalp avulsions, and articles discussing delayed scalp replantation were excluded. Data extracted included demographics, percent of scalp affected, mechanism, operative technique, and postoperative outcomes. Statistical analysis was performed using Mann-Whitney U tests, Kruskal-Wallis, and chi-squared tests. RESULTS:  From a total of 704 initial results, 61 studies were included for analysis comprising 149 scalps. Complete survival was achieved in 54.7%, partial survival in 38.9%, and failure in 6.7%. Total ischemia time greater than 12 hours was associated with complete replant failure. Arterial anastomoses appeared to protect against complete loss. The number of venous repairs, proportion of venous-to-arterial repairs, use of vein grafts, thromboprophylaxis, or intraoperative complications did not affect outcomes. Patients required significant volumes of blood products, which was associated with partial success. Salvage rate after unplanned return to the operating room was 60.0%. Normal hair growth was achieved in all surviving native scalp tissue. CONCLUSION:  Scalp replantations, while technically challenging, are the ideal treatment for scalp avulsions. Fortunately, these have high rates of success. And as a focal point of a patient's appearance, this is invaluable in restoration of a sense of normalcy.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleSystematic Review
Indexed MeSH termsAnticoagulantsHumansMicrosurgeryReplantationScalpVenous Thromboembolism

Summary

A systematic review of 61 studies comprising 149 replanted scalps found complete survival in 54.7%, partial survival in 38.9%, and failure in 6.7%; ischemia time exceeding 12 hours was linked to complete failure, while arterial anastomosis appeared protective against total loss.

Context

This systematic review analyzed 61 studies comprising 149 microvascular scalp replantation cases, reporting a 54.7% complete survival rate and identifying total ischemia time over 12 hours as associated with complete replant failure. The study makes no mention of leech therapy or hirudotherapy. While scalp replantation can involve venous congestion management—a setting where medicinal leeches are sometimes used adjunctively—this review does not address that aspect, and the number of venous repairs or thromboprophylaxis did not significantly affect outcomes.

Citation

Reference (Vancouver style)

Kotamarti VS, Heiman AJ, Camargo L, Ricci JA. Identifying factors affecting outcomes in scalp replantation: a systematic review of the literature. J Reconstr Microsurg. 2022;38(1):56-63. doi:10.1055/s-0041-1729876. PMID: 34010964

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.